VIP as a potential therapeutic agent in Gram negative sepsis

Hiba Ibrahim, Paul Barrow, Neil Foster*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.

Original languageEnglish
Pages (from-to)308-315
Number of pages8
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Issue number4
Publication statusPrint publication - 3 Dec 2012
Externally publishedYes


  • Cytokine
  • Inflammation
  • Sepsis
  • Transcription bacteria
  • VIP


Dive into the research topics of 'VIP as a potential therapeutic agent in Gram negative sepsis'. Together they form a unique fingerprint.

Cite this